BullFrog AI Holdings (BFRG) Company Report

BullFrog AI Holdings, Inc. (BFRG) released its annual letter to shareholders, highlighting significant progress in 2025 and outlining commercial priorities and potential catalysts for 2026.
The company entered a commercial collaboration with Sygnature Discovery in Q2 2025, expected to generate significant revenue through 2028, and is engaged in multiple advanced discussions with large pharmaceutical organizations for potential commercial transactions.
A major achievement in 2025 was the launch of bfPREP™, an AI-powered data preparation module, and a successful collaboration with Eleison Pharmaceuticals demonstrated real-world deployment of its platforms, with insights accepted for presentation at the 2026 ASCO Gastrointestinal Cancers Symposium on January 9, 2026.
BullFrog AI maintains a lean cost structure with an annual burn of approximately $6.2 million and has financing flexibility through a $10 million equity line of credit and an ATM.

Dec 30, 2025, 10:00 PM

BullFrog AI Holdings, Inc. enters into $10.0 million common stock purchase agreement

BFRG

New Projects/Investments

BullFrog AI Holdings, Inc. (BFRG) entered into a Purchase Agreement and a Registration Rights Agreement with Lincoln Park Capital Fund, LLC on September 15, 2025.
Under the Purchase Agreement, Lincoln Park committed to purchase up to $10.0 million of BFRG's common stock over a 36-month period, at the Company's discretion.
As consideration for this commitment, BFRG will issue 147,682 shares of Common Stock to Lincoln Park.
The Company expects to use any proceeds from these sales for working capital, capital expenditures, and general corporate purposes.
The aggregate number of shares that can be sold to Lincoln Park is capped at 2,048,936 shares (19.99% of outstanding shares), unless stockholder approval is obtained or the average price per share equals or exceeds $1.4053.

Sep 16, 2025, 8:46 PM

Get instant answers from SEC filings, earnings calls & more